Incretins, insulin secretion and Type 2 diabetes mellitus

[1]  M. Nauck,et al.  Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes , 2006, Diabetologia.

[2]  J. Holst,et al.  Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man , 1993, Digestive Diseases and Sciences.

[3]  J. Holst,et al.  Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7–36 amide] in the fasting state in healthy subjects , 1995, Acta Diabetologica.

[4]  J. Holst,et al.  Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.

[5]  W. Creutzfeldt,et al.  Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption , 1983, Diabetologia.

[6]  J. J. Hoist.  Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours , 1983, Diabetologia.

[7]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[8]  T. Hansen,et al.  The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. , 2003, The Journal of clinical endocrinology and metabolism.

[9]  J. Holst,et al.  Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects , 2003, Regulatory Peptides.

[10]  J. Holst,et al.  GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine , 2003, Regulatory Peptides.

[11]  J. Holst,et al.  Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. , 2003, The Journal of clinical endocrinology and metabolism.

[12]  D. Drucker,et al.  International Union of Pharmacology. XXXV. The Glucagon Receptor Family , 2003, Pharmacological Reviews.

[13]  J. Holst,et al.  The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. , 2003, Diabetes.

[14]  D. Drucker.  Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. , 2003, Molecular endocrinology.

[15]  Robert A. Rizza,et al.  β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes , 2003, Diabetes.

[16]  J. Holst,et al.  Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. , 2003, The Journal of clinical endocrinology and metabolism.

[17]  Robert A Rizza,et al.  Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. , 2003, Diabetes.

[18]  P. Flatt,et al.  Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. , 2002, The Journal of endocrinology.

[19]  J. Holst.  Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1 , 2002, Diabetes/metabolism research and reviews.

[20]  R. Pederson,et al.  Glucose-dependent Insulinotropic Polypeptide Activates the Raf-Mek1/2-ERK1/2 Module via a Cyclic AMP/cAMP-dependent Protein Kinase/Rap1-mediated Pathway* , 2002, The Journal of Biological Chemistry.

[21]  J. Holst,et al.  Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients , 2002, Diabetologia.

[22]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[23]  J. Holst,et al.  Incretin hormones--an update. , 2001, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[24]  J. Holst,et al.  Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. , 2001, Diabetes.

[25]  K. Petersen,et al.  Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans , 2001, Diabetologia.

[26]  D. Hörsch,et al.  Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. , 2001, Molecular endocrinology.

[27]  J. Holst,et al.  Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.

[28]  J. Holst,et al.  Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. , 2001, Diabetes.

[29]  R. Pederson,et al.  A New Pathway for Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor Signaling , 2001, The Journal of Biological Chemistry.

[30]  R. Pederson,et al.  Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. , 2001, Diabetes.

[31]  J. Holst,et al.  Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. , 2001, Diabetes.

[32]  T. Vilsbøll,et al.  No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP‐1 and intravenous glucose , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[33]  C. Ørskov,et al.  Colocalization of GLP‐1 and GIP in Human and Porcine Intestine , 2000, Annals of the New York Academy of Sciences.

[34]  Jie Zhou,et al.  Glucagon-Like Peptide-1 Induces Cell Proliferation and Pancreatic-Duodenum Homeobox-1 Expression and Increases Endocrine Cell Mass in the Pancreas of Old, Glucose-Intolerant Rats. , 2000, Endocrinology.

[35]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[36]  J. Habener,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society Glucose-Dependent Insulinotropic Polypeptide Confers Early Phase Insulin Release to Oral Glucose in Rats: Demonstration by a Receptor Antagonist* , 2000 .

[37]  J. Holst,et al.  Evaluation of beta-cell secretory capacity using glucagon-like peptide 1. , 2000, Diabetes care.

[38]  S. Bonner-Weir,et al.  Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. , 2000, Diabetes.

[39]  D. Drucker,et al.  The Glucagon Receptor Family , 2000 .

[40]  J. Egan,et al.  Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. , 2000, Endocrinology.

[41]  W. Schmiegel,et al.  Lack of germline mutations in the preproglucagon gene region coding for glucagon-like peptide 1 in Type 2 diabetic (NIDDM) patients. , 2000, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[42]  J. Miyazaki,et al.  Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Jie Zhou,et al.  Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. , 1999, Diabetes.

[44]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[45]  Rolf Mentlein,et al.  Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.

[46]  J. Holst,et al.  Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations , 1999, Diabetologia.

[47]  J. Holst.  Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential , 1999, Trends in Endocrinology & Metabolism.

[48]  M. Prentki,et al.  Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells , 1999, Diabetologia.

[49]  C. Beglinger,et al.  rapid communication Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2 , 2022 .

[50]  S. Rössner,et al.  Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. , 1999, International Journal of Obesity.

[51]  S. Bloom,et al.  Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. , 1999, Diabetes.

[52]  R. Turner.  The U.K. Prospective Diabetes Study: A review , 1998, Diabetes Care.

[53]  J. Holst,et al.  Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia , 1998, Diabetologia.

[54]  R. Pederson,et al.  Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. , 1998, Diabetes.

[55]  M. Denaro,et al.  Roles of amylin in diabetes and in regulation of nutrient load. , 1998, Nutrition.

[56]  T. Hansen,et al.  Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells , 1998, Diabetologia.

[57]  J. Holst,et al.  Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1 , 1998, Pflügers Archiv.

[58]  A. Astrup,et al.  Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.

[59]  J. Holst,et al.  Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. , 1997, American journal of physiology. Endocrinology and metabolism.

[60]  J. Holst,et al.  The pathogenesis of NIDDM involves a defective expression of the GIP receptor , 1997, Diabetologia.

[61]  P. Rorsman,et al.  Glucagon-Like Peptide I and Glucose-Dependent Insulinotropic Polypeptide Stimulate Ca2+-Induced Secretion in Rat α-Cells by a Protein Kinase A–Mediated Mechanism , 1997, Diabetes.

[62]  J. Levy,et al.  Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM , 1997, Diabetologia.

[63]  L. B. Knudsen,et al.  Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. , 1996, European journal of pharmacology.

[64]  K. Tsuda,et al.  Identification of Two Missense Mutations in the GIP Receptor Gene: A Functional Study and Association Analysis with NIDDM: No Evidence of Association with Japanese NIDDM Subjects , 1996, Diabetes.

[65]  T. Usdin,et al.  Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. , 1996, The Journal of clinical investigation.

[66]  J. Holst,et al.  Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM , 1996, Diabetologia.

[67]  A. Joyner,et al.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene , 1996, Nature Medicine.

[68]  J. Holst,et al.  Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. , 1996, European journal of endocrinology.

[69]  J. Holst,et al.  Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. , 1996, The American journal of physiology.

[70]  I. Svendsen,et al.  Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits , 1996, Diabetes.

[71]  J. Holst,et al.  Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. , 1996, Scandinavian journal of gastroenterology.

[72]  J. Holst,et al.  Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients , 1996, Diabetes Care.

[73]  J. Holst,et al.  Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.

[74]  J. Holst,et al.  Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). , 1995, Scandinavian journal of gastroenterology.

[75]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[76]  B. Göke,et al.  Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. , 1995, Endocrine reviews.

[77]  J. Brown,et al.  Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion. , 1995, The American journal of physiology.

[78]  J. Holst,et al.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[79]  B. Göke,et al.  Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9–39) Amide , 1995, Diabetes.

[80]  D. Smith,et al.  Glucagon-like peptide-1 is a physiological incretin in rat. , 1995, The Journal of clinical investigation.

[81]  K. Minaker,et al.  The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjects , 1994, Regulatory Peptides.

[82]  M. Brownstein,et al.  Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. , 1993, Endocrinology.

[83]  M. Nauck,et al.  Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. , 1993, The Journal of clinical endocrinology and metabolism.

[84]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[85]  J. Habener,et al.  Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. , 1992, Endocrinology.

[86]  M. Nauck,et al.  Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. , 1989, The Journal of clinical endocrinology and metabolism.

[87]  J. Holst,et al.  Oxyntomodulin (glicentin-(33–69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs , 1988, Regulatory Peptides.

[88]  T. Krarup.  Immunoreactive gastric inhibitory polypeptide. , 1988, Endocrine reviews.

[89]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[90]  Suzuki,et al.  Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[91]  S. Madsbad,et al.  Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus. , 1987, Metabolism: clinical and experimental.

[92]  J. Holst,et al.  Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. , 1986, Endocrinology.

[93]  L. Orci,et al.  Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. , 1986, The Journal of biological chemistry.

[94]  R. Eaton,et al.  Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. , 1986, The Journal of clinical endocrinology and metabolism.

[95]  H. Kehlet,et al.  Discrepancy Between Plasma C-Peptide and Insulin Response to Oral and Intravenous Glucose , 1983, Diabetes.

[96]  J. Holst.  Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours. , 1983, Diabetologia.

[97]  Graeme I. Bell,et al.  Exon duplication and divergence in the human preproglucagon gene , 1983, Nature.

[98]  W. Creutzfeldt,et al.  Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats. , 1982, Endocrinology.

[99]  K. Lauritsen,et al.  Gastric inhibitory polypeptide and insulin release in response to oral and intravenous glucose in coeliac disease. , 1982, Scandinavian journal of gastroenterology.

[100]  J. Holst,et al.  Depression of insulin release with anti-GIP serum after oral glucose in rats , 1980, Regulatory Peptides.

[101]  W. Creutzfeldt,et al.  Gastric inhibitory polypeptide. , 1980, Clinics in gastroenterology.

[102]  K. Lauritsen,et al.  Gastric inhibitory polypeptide (GIP) and insulin release after small-bowel resection in man. , 1980, Scandinavian journal of gastroenterology.

[103]  J. Brown,et al.  Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. , 1978, The Journal of clinical investigation.

[104]  J. Brown,et al.  Stimulation of insulin secretion by gastric inhibitory polypeptide in man. , 1973, The Journal of clinical endocrinology and metabolism.

[105]  D. Kipnis,et al.  Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. , 1967, The Journal of clinical investigation.

[106]  N. Mcintyre,et al.  Intestinal factors in the control of insulin secretion. , 1965, The Journal of clinical endocrinology and metabolism.